Logo image of VKTX

VIKING THERAPEUTICS INC (VKTX) Stock Fundamental Analysis

NASDAQ:VKTX - Nasdaq - US92686J1060 - Common Stock - Currency: USD

34.07  +2.44 (+7.71%)

After market: 35.1 +1.03 (+3.02%)

Fundamental Rating

3

Overall VKTX gets a fundamental rating of 3 out of 10. We evaluated VKTX against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VKTX has reported negative net income.
VKTX had a negative operating cash flow in the past year.
In the past 5 years VKTX always reported negative net income.
In the past 5 years VKTX always reported negative operating cash flow.
VKTX Yearly Net Income VS EBIT VS OCF VS FCFVKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of VKTX (-10.57%) is better than 86.86% of its industry peers.
VKTX's Return On Equity of -10.88% is amongst the best of the industry. VKTX outperforms 90.05% of its industry peers.
Industry RankSector Rank
ROA -10.57%
ROE -10.88%
ROIC N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
VKTX Yearly ROA, ROE, ROICVKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VKTX Yearly Profit, Operating, Gross MarginsVKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, VKTX has more shares outstanding
VKTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VKTX Yearly Shares OutstandingVKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VKTX Yearly Total Debt VS Total AssetsVKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 80.10 indicates that VKTX is not in any danger for bankruptcy at the moment.
VKTX's Altman-Z score of 80.10 is amongst the best of the industry. VKTX outperforms 98.93% of its industry peers.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 80.1
ROIC/WACCN/A
WACCN/A
VKTX Yearly LT Debt VS Equity VS FCFVKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

VKTX has a Current Ratio of 36.47. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VKTX (36.47) is better than 98.58% of its industry peers.
A Quick Ratio of 36.47 indicates that VKTX has no problem at all paying its short term obligations.
The Quick ratio of VKTX (36.47) is better than 98.58% of its industry peers.
Industry RankSector Rank
Current Ratio 36.47
Quick Ratio 36.47
VKTX Yearly Current Assets VS Current LiabilitesVKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

VKTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.70%.
EPS 1Y (TTM)-8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VKTX will show a very strong growth in Earnings Per Share. The EPS will grow by 43.75% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-59.15%
EPS Next 2Y-46.69%
EPS Next 3Y-34.83%
EPS Next 5Y43.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VKTX Yearly Revenue VS EstimatesVKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
VKTX Yearly EPS VS EstimatesVKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VKTX Price Earnings VS Forward Price EarningsVKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VKTX Per share dataVKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

VKTX's earnings are expected to decrease with -34.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.69%
EPS Next 3Y-34.83%

More info and screens

0

5. Dividend

5.1 Amount

VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

NASDAQ:VKTX (2/21/2025, 8:00:01 PM)

After market: 35.1 +1.03 (+3.02%)

34.07

+2.44 (+7.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-05 2025-02-05/amc
Earnings (Next)04-22 2025-04-22/amc
Inst Owners75%
Inst Owner Change0.49%
Ins Owners2.8%
Ins Owner Change0.02%
Market Cap3.80B
Analysts87.62
Price Target103.77 (204.58%)
Short Float %22.42%
Short Ratio6.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.87%
Min EPS beat(2)14.36%
Max EPS beat(2)27.38%
EPS beat(4)4
Avg EPS beat(4)13.32%
Min EPS beat(4)3.25%
Max EPS beat(4)27.38%
EPS beat(8)5
Avg EPS beat(8)5.18%
EPS beat(12)7
Avg EPS beat(12)4.71%
EPS beat(16)10
Avg EPS beat(16)4.58%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.14%
EPS NQ rev (1m)1.43%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)-5.72%
EPS NY rev (3m)-3.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.17
P/tB 4.17
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS8.17
TBVpS8.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.57%
ROE -10.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.47
Quick Ratio 36.47
Altman-Z 80.1
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28%
EPS Next Y-59.15%
EPS Next 2Y-46.69%
EPS Next 3Y-34.83%
EPS Next 5Y43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.35%
EBIT Next 3Y-23.28%
EBIT Next 5Y12.17%
FCF growth 1Y-11.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.36%
OCF growth 3YN/A
OCF growth 5YN/A